View Future GrowthNovozymes 과거 순이익 실적과거 기준 점검 5/6Novozymes은 연평균 5.9%의 비율로 수입이 증가해 온 반면, Chemicals 산업은 수입이 21.2% 감소했습니다. 매출은 연평균 18.7%의 비율로 증가했습니다. Novozymes의 자기자본이익률은 5.7%이고 순이익률은 14.7%입니다.핵심 정보5.89%순이익 성장률-2.93%주당순이익(EPS) 성장률Chemicals 산업 성장률12.41%매출 성장률18.69%자기자본이익률5.66%순이익률14.70%다음 순이익 업데이트05 Nov 2026최근 과거 실적 업데이트Reported Earnings • May 06First quarter 2026 earnings released: EPS: €0.43 (vs €0.40 in 1Q 2025)First quarter 2026 results: EPS: €0.43 (up from €0.40 in 1Q 2025). Revenue: €1.12b (up 3.9% from 1Q 2025). Net income: €199.1m (up 7.0% from 1Q 2025). Profit margin: 18% (in line with 1Q 2025). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany.Reported Earnings • Mar 03Full year 2025 earnings released: EPS: €1.25 (vs €1.10 in FY 2024)Full year 2025 results: EPS: €1.25 (up from €1.10 in FY 2024). Revenue: €4.16b (up 8.5% from FY 2024). Net income: €583.6m (up 91% from FY 2024). Profit margin: 14% (up from 8.0% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: €0.29 (vs €0.33 in 3Q 2024)Third quarter 2025 results: EPS: €0.29 (down from €0.33 in 3Q 2024). Revenue: €1.06b (up 4.4% from 3Q 2024). Net income: €138.0m (down 11% from 3Q 2024). Profit margin: 13% (down from 15% in 3Q 2024). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Chemicals industry in Germany.모든 업데이트 보기Recent updatesDeclared Dividend • 10hFirst half dividend of kr.2.35 announcedShareholders will receive a dividend of kr.2.35. Ex-date: 25th August 2026 Payment date: 27th August 2026 Dividend yield will be 4.9%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is covered by both earnings (65% earnings payout ratio) and cash flows (53% cash payout ratio). The dividend has increased by an average of 6.4% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 48% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공고 • Aug 21Novonesis A/S Approves Interim Dividend for the First Six Months of 2026, Payable on August 27, 2026Novozymes A/S announced Interim dividend for first six months of 2026 was approved by Board of Directors at DKK 2.35 (EUR 0.31) per share. The dividend will be disbursed on August 27, 2026, with August 24, 2026, as the last trading day with dividend.공고 • Aug 20Novozymes A/S (CPSE:NSIS B) announces an Equity Buyback for €1,000 million worth of its shares.Novozymes A/S (CPSE:NSIS B) announces a share repurchase program. Under the program, the company will repurchase up to €1,000 million worth of its shares. The purchased shares will be cancelled or retained to meet obligations arising from employee share-based incentive programs. The program will run through end of 2029.공고 • Aug 14Novonesis Launches Optiva Triticum to Help Pasta Manufacturers Navigate Wheat Volatility Without Compromising QualityNovonesis announced the launch of Optiva Triticum, a new biosolution that helps pasta manufacturers increase flexibility in wheat sourcing while maintaining the texture, firmness and eating experience consumers expect. Optiva Triticum enables greater use of soft wheat flour in pasta applications while supporting consistent quality across varying flour qualities and protein levels. Designed specifically for pasta production, Optiva Triticum strengthens and connects proteins within the pasta matrix, creating a more robust protein network. This improves the structural integrity of pasta made with different wheat flours, helping manufacturers achieve greater formulation flexibility without compromising product performance. In pilot-scale evaluations, pasta produced with Optiva Triticum delivered firmness improvements of up to 25% in spaghetti and up to 11% in short-cut pasta compared with control samples. The solution also reduced cooking water turbidity by approximately 25%, indicating lower starch release during cooking and contributing to an improved cooking experience. Consumer research conducted by Novonesis found that firmness and stickiness are among the most important factors consumers used to evaluate pasta quality. These qualities are usually staples of durum wheat, but Optiva Triticum allows producers to use a wider range of wheat flours while maintaining product quality. By enabling greater flexibility in flour sourcing and formulation, the solution can help manufacturers make more effective use of available raw materials while continuing to deliver a consistent consumer experience. Optiva Triticum helps future-proof pasta production and support the delivery of quality everyday foods, no matter the wheat.공고 • Aug 12Novozymes A/S (CPSE:NSIS B) signed a letter of intent to acquire remaining 77% stake in Microbiogen Pty Ltd.Novozymes A/S (CPSE:NSIS B) signed a letter of intent to acquire remaining 77% stake in Microbiogen Pty Ltd. on August 10, 2026. Prior to the acquisition, Novozymes A/S owns 23% stake in Microbiogen Pty Ltd. Upon completion, Novozymes A/S will own 100% stake in Microbiogen Pty Ltd. As part of the agreement, Novonesis will continue to support MicroBioGen's existing partners and ensure continuity in its collaborations. The transaction is subject to customary regulatory approvals, including by the ACCC (Australia's national competition, consumer, fair trading and product safety regulator). Robbie McLaren, Lydia Torne, Ludmilla Le Grand, Simon Pritchard, Aoife McCabe, Karl Mah, Sarah Gadd, Christian McDermott, Clare Nida and Thomas Lane of Latham & Watkins LLP acted as legal advisor for Novozymes A/S.Reported Earnings • May 06First quarter 2026 earnings released: EPS: €0.43 (vs €0.40 in 1Q 2025)First quarter 2026 results: EPS: €0.43 (up from €0.40 in 1Q 2025). Revenue: €1.12b (up 3.9% from 1Q 2025). Net income: €199.1m (up 7.0% from 1Q 2025). Profit margin: 18% (in line with 1Q 2025). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany.공고 • Mar 24Novonesis A/S Approves Dividend on A and B ShareNovozymes A/S announced at the AGM held on March 23, 2026, approved distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share.Upcoming Dividend • Mar 17Upcoming dividend of kr.4.25 per shareEligible shareholders must have bought the stock before 24 March 2026. Payment date: 26 March 2026. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (4.0%).Reported Earnings • Mar 03Full year 2025 earnings released: EPS: €1.25 (vs €1.10 in FY 2024)Full year 2025 results: EPS: €1.25 (up from €1.10 in FY 2024). Revenue: €4.16b (up 8.5% from FY 2024). Net income: €583.6m (up 91% from FY 2024). Profit margin: 14% (up from 8.0% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.Declared Dividend • Feb 28Dividend of kr.4.25 announcedShareholders will receive a dividend of kr.4.25. Ex-date: 24th March 2026 Payment date: 26th March 2026 Dividend yield will be 9.1%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is covered by both earnings (59% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 17% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공고 • Feb 27Novozymes A/S, Annual General Meeting, Mar 23, 2026Novozymes A/S, Annual General Meeting, Mar 23, 2026, at 16:00 Romance Standard Time. Location: gammel venlighedsvej 14, dk-2970 hoersholm, Denmark공고 • Feb 25+ 3 more updatesNovozymes A/S Proposes Dividend for Full Year 2025Novozymes A/S proposed dividend of DKK 4.25 per share. DKK 2.25 per share interim dividend paid August 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit.Buy Or Sell Opportunity • Jan 22Now 21% overvaluedThe stock has been flat over the last 90 days, currently trading at €55.22. The fair value is estimated to be €45.45, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 3.2%. For the next 3 years, revenue is forecast to grow by 6.3% per annum. Earnings are also forecast to grow by 18% per annum over the same time period.Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: €0.29 (vs €0.33 in 3Q 2024)Third quarter 2025 results: EPS: €0.29 (down from €0.33 in 3Q 2024). Revenue: €1.06b (up 4.4% from 3Q 2024). Net income: €138.0m (down 11% from 3Q 2024). Profit margin: 13% (down from 15% in 3Q 2024). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Chemicals industry in Germany.공고 • Nov 06Novozymes A/S Revises Earnings Guidance for the Year 2025Novozymes A/S revised earnings guidance for the year 2025. For the year, the company expects organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in fourth quarter following favorable timing in third quarter. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%).Board Change • Sep 11High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Employee Representative Director Lars Koppler was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.매출 및 비용 세부 내역Novozymes가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이XTRA:NZM2 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Jun 264,29763296947231 Mar 264,19959794446231 Dec 254,15858491244930 Sep 254,14254787244630 Jun 254,09856583943631 Mar 254,05845981042931 Dec 243,83430676641330 Sep 243,47131466937330 Jun 243,04728357532731 Mar 242,63633449429331 Dec 232,40240644627130 Sep 232,39043044127030 Jun 232,38246044627231 Mar 232,39048744127031 Dec 222,36049443026730 Sep 222,26846044326230 Jun 222,18641841825731 Mar 222,09041640325731 Dec 212,00942338026630 Sep 211,95842733526830 Jun 211,91440932227431 Mar 211,88338931027031 Dec 201,88338030925630 Sep 201,92041530924830 Jun 201,95540532625431 Mar 201,96843933526431 Dec 191,92442232926330 Sep 191,92341133426230 Jun 191,91743432126031 Mar 191,92241731524931 Dec 181,92743231324830 Sep 181,92442731125430 Jun 181,91542931024731 Mar 181,92042332024831 Dec 171,95241933225530 Sep 171,95842133425530 Jun 171,93441233225431 Mar 171,91941432825131 Dec 161,90241032525130 Sep 161,86439432724730 Jun 161,88339433325331 Mar 161,88338433125931 Dec 151,87637833025430 Sep 151,840366320255양질의 수익: NZM2는 고품질 수익을 보유하고 있습니다.이익 마진 증가: NZM2의 현재 순 이익률 (14.7%)은 지난해 (13.8%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: NZM2의 수익은 지난 5년 동안 연평균 5.9% 증가했습니다.성장 가속화: 지난 1년간 NZM2 의 수익 증가율(11.8%)은 연간 평균(5.9%)을 초과합니다.수익 대 산업: NZM2의 지난 1년 수익 증가율(11.8%)은 Chemicals 업계의 -13.3%를 상회했습니다.자기자본이익률높은 ROE: NZM2의 자본 수익률(5.7%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/23 10:08종가2026/08/21 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Novozymes A/S는 28명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Cezara LozneanuBarclaysAlexander SloaneBarclaysSebastian SatzBarclays25명의 분석가 더 보기
Reported Earnings • May 06First quarter 2026 earnings released: EPS: €0.43 (vs €0.40 in 1Q 2025)First quarter 2026 results: EPS: €0.43 (up from €0.40 in 1Q 2025). Revenue: €1.12b (up 3.9% from 1Q 2025). Net income: €199.1m (up 7.0% from 1Q 2025). Profit margin: 18% (in line with 1Q 2025). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany.
Reported Earnings • Mar 03Full year 2025 earnings released: EPS: €1.25 (vs €1.10 in FY 2024)Full year 2025 results: EPS: €1.25 (up from €1.10 in FY 2024). Revenue: €4.16b (up 8.5% from FY 2024). Net income: €583.6m (up 91% from FY 2024). Profit margin: 14% (up from 8.0% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.
Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: €0.29 (vs €0.33 in 3Q 2024)Third quarter 2025 results: EPS: €0.29 (down from €0.33 in 3Q 2024). Revenue: €1.06b (up 4.4% from 3Q 2024). Net income: €138.0m (down 11% from 3Q 2024). Profit margin: 13% (down from 15% in 3Q 2024). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Chemicals industry in Germany.
Declared Dividend • 10hFirst half dividend of kr.2.35 announcedShareholders will receive a dividend of kr.2.35. Ex-date: 25th August 2026 Payment date: 27th August 2026 Dividend yield will be 4.9%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is covered by both earnings (65% earnings payout ratio) and cash flows (53% cash payout ratio). The dividend has increased by an average of 6.4% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 48% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공고 • Aug 21Novonesis A/S Approves Interim Dividend for the First Six Months of 2026, Payable on August 27, 2026Novozymes A/S announced Interim dividend for first six months of 2026 was approved by Board of Directors at DKK 2.35 (EUR 0.31) per share. The dividend will be disbursed on August 27, 2026, with August 24, 2026, as the last trading day with dividend.
공고 • Aug 20Novozymes A/S (CPSE:NSIS B) announces an Equity Buyback for €1,000 million worth of its shares.Novozymes A/S (CPSE:NSIS B) announces a share repurchase program. Under the program, the company will repurchase up to €1,000 million worth of its shares. The purchased shares will be cancelled or retained to meet obligations arising from employee share-based incentive programs. The program will run through end of 2029.
공고 • Aug 14Novonesis Launches Optiva Triticum to Help Pasta Manufacturers Navigate Wheat Volatility Without Compromising QualityNovonesis announced the launch of Optiva Triticum, a new biosolution that helps pasta manufacturers increase flexibility in wheat sourcing while maintaining the texture, firmness and eating experience consumers expect. Optiva Triticum enables greater use of soft wheat flour in pasta applications while supporting consistent quality across varying flour qualities and protein levels. Designed specifically for pasta production, Optiva Triticum strengthens and connects proteins within the pasta matrix, creating a more robust protein network. This improves the structural integrity of pasta made with different wheat flours, helping manufacturers achieve greater formulation flexibility without compromising product performance. In pilot-scale evaluations, pasta produced with Optiva Triticum delivered firmness improvements of up to 25% in spaghetti and up to 11% in short-cut pasta compared with control samples. The solution also reduced cooking water turbidity by approximately 25%, indicating lower starch release during cooking and contributing to an improved cooking experience. Consumer research conducted by Novonesis found that firmness and stickiness are among the most important factors consumers used to evaluate pasta quality. These qualities are usually staples of durum wheat, but Optiva Triticum allows producers to use a wider range of wheat flours while maintaining product quality. By enabling greater flexibility in flour sourcing and formulation, the solution can help manufacturers make more effective use of available raw materials while continuing to deliver a consistent consumer experience. Optiva Triticum helps future-proof pasta production and support the delivery of quality everyday foods, no matter the wheat.
공고 • Aug 12Novozymes A/S (CPSE:NSIS B) signed a letter of intent to acquire remaining 77% stake in Microbiogen Pty Ltd.Novozymes A/S (CPSE:NSIS B) signed a letter of intent to acquire remaining 77% stake in Microbiogen Pty Ltd. on August 10, 2026. Prior to the acquisition, Novozymes A/S owns 23% stake in Microbiogen Pty Ltd. Upon completion, Novozymes A/S will own 100% stake in Microbiogen Pty Ltd. As part of the agreement, Novonesis will continue to support MicroBioGen's existing partners and ensure continuity in its collaborations. The transaction is subject to customary regulatory approvals, including by the ACCC (Australia's national competition, consumer, fair trading and product safety regulator). Robbie McLaren, Lydia Torne, Ludmilla Le Grand, Simon Pritchard, Aoife McCabe, Karl Mah, Sarah Gadd, Christian McDermott, Clare Nida and Thomas Lane of Latham & Watkins LLP acted as legal advisor for Novozymes A/S.
Reported Earnings • May 06First quarter 2026 earnings released: EPS: €0.43 (vs €0.40 in 1Q 2025)First quarter 2026 results: EPS: €0.43 (up from €0.40 in 1Q 2025). Revenue: €1.12b (up 3.9% from 1Q 2025). Net income: €199.1m (up 7.0% from 1Q 2025). Profit margin: 18% (in line with 1Q 2025). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany.
공고 • Mar 24Novonesis A/S Approves Dividend on A and B ShareNovozymes A/S announced at the AGM held on March 23, 2026, approved distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share.
Upcoming Dividend • Mar 17Upcoming dividend of kr.4.25 per shareEligible shareholders must have bought the stock before 24 March 2026. Payment date: 26 March 2026. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (4.0%).
Reported Earnings • Mar 03Full year 2025 earnings released: EPS: €1.25 (vs €1.10 in FY 2024)Full year 2025 results: EPS: €1.25 (up from €1.10 in FY 2024). Revenue: €4.16b (up 8.5% from FY 2024). Net income: €583.6m (up 91% from FY 2024). Profit margin: 14% (up from 8.0% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.
Declared Dividend • Feb 28Dividend of kr.4.25 announcedShareholders will receive a dividend of kr.4.25. Ex-date: 24th March 2026 Payment date: 26th March 2026 Dividend yield will be 9.1%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is covered by both earnings (59% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 17% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공고 • Feb 27Novozymes A/S, Annual General Meeting, Mar 23, 2026Novozymes A/S, Annual General Meeting, Mar 23, 2026, at 16:00 Romance Standard Time. Location: gammel venlighedsvej 14, dk-2970 hoersholm, Denmark
공고 • Feb 25+ 3 more updatesNovozymes A/S Proposes Dividend for Full Year 2025Novozymes A/S proposed dividend of DKK 4.25 per share. DKK 2.25 per share interim dividend paid August 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit.
Buy Or Sell Opportunity • Jan 22Now 21% overvaluedThe stock has been flat over the last 90 days, currently trading at €55.22. The fair value is estimated to be €45.45, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 3.2%. For the next 3 years, revenue is forecast to grow by 6.3% per annum. Earnings are also forecast to grow by 18% per annum over the same time period.
Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: €0.29 (vs €0.33 in 3Q 2024)Third quarter 2025 results: EPS: €0.29 (down from €0.33 in 3Q 2024). Revenue: €1.06b (up 4.4% from 3Q 2024). Net income: €138.0m (down 11% from 3Q 2024). Profit margin: 13% (down from 15% in 3Q 2024). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Chemicals industry in Germany.
공고 • Nov 06Novozymes A/S Revises Earnings Guidance for the Year 2025Novozymes A/S revised earnings guidance for the year 2025. For the year, the company expects organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in fourth quarter following favorable timing in third quarter. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%).
Board Change • Sep 11High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Employee Representative Director Lars Koppler was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.